Mitigating the toxic effects of anticancer immunotherapy (Q38180319)

30 August 2017

Mitigating the toxic effects of anticancer immunotherapy (English)

1 reference

30 August 2017

1 reference

1

Tara C Gangadhar

1 reference

30 August 2017

Robert H Vonderheide

2

1 reference

PubMed ID

24445516

30 August 2017

language of work or name

English

0 references

publication date

21 January 2014

1 reference

Nature Reviews Clinical Oncology

30 August 2017

1 reference

30 August 2017

11

1 reference

30 August 2017

91-99

1 reference

30 August 2017

2

1 reference

A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma.

30 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

Immunostimulatory monoclonal antibodies for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

Management of immune-related adverse events and kinetics of response with ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

Ipilimumab-associated colitis: CT findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

Endocrine side effects induced by immune checkpoint inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

Thyroid dysfunction from antineoplastic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

Strength of PD-1 signaling differentially affects T-cell effector functions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

Tumor Immunotherapy Directed at PD-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

Agonistic CD40 antibodies and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

A translational bridge to cancer immunotherapy: exploiting costimulation and target antigens for active and passive T cell immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

Hepatotoxicity with combination of vemurafenib and ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

Clinical cancer advances 2012 and neoadjuvant chemoradiotherapy in operable gastroesophageal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

Combination checkpoint blockade--taking melanoma immunotherapy to the next level.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

The road to recovery: translating PD-1 biology into clinical benefit

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.245

Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24445516

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24445516

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Lymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-regulated activation of Th2 responses

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24445516

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRCLINONC.2013.245

1 reference

30 August 2017

1 reference

PubMed ID

24445516